Quarterly ResultMay 6, 2026, 06:14 AM
LivaNova Q1 Revenue +14.3%; Raises FY26 Guidance; Gets FDA OSA Approval
AI Summary
LivaNova PLC reported strong first-quarter 2026 financial results, with revenue increasing 14.3% to $362.3 million and adjusted diluted EPS reaching $0.98. The company also raised its full-year 2026 revenue growth guidance to 7.0%-8.0% and adjusted diluted EPS guidance to $4.20-$4.30. Additionally, LivaNova received U.S. FDA premarket approval for its aura6000 System for moderate to severe obstructive sleep apnea, marking a significant regulatory and clinical milestone. The company will host a business update conference call today, May 6, 2026.
Key Highlights
- Received U.S. FDA premarket approval for aura6000 System for obstructive sleep apnea.
- Q1 2026 revenue increased 14.3% to $362.3 million.
- Q1 2026 adjusted diluted EPS was $0.98.
- Raised full-year 2026 revenue growth guidance to 7.0%-8.0% constant-currency.
- Raised full-year 2026 adjusted diluted EPS guidance to $4.20-$4.30.
- Cardiopulmonary revenue grew 18.3% to $208.7 million.
- Neuromodulation revenue grew 9.3% to $151.8 million.
- Maintained full-year 2026 adjusted free cash flow guidance of $160M-$180M.